Iovance Bio down 12% premarket following presentation of TIL data in lung cancer

|About: Iovance Biotherapeutic... (IOVA)|By:, SA News Editor

Iovance Biotherapeutics (NASDAQ:IOVA) slumps 12% premarket on increased volume on the heels of a presentation at the H.C. Wainwright Global Investor Conference in New York City yesterday.

The action appears connected to an abstract on TIL for the World Conference on Lung Cancer. Specifically, two of six treated patients progressed after treatment (albeit a small data set).

Subscribe for full text news in your inbox